Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseClinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Randomized, Open-label, Active-controlled, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
The purpose of this study was to explore the efficacy and safety of the weekly intraocular pressure change of the TFC-003 group and the dorzolamid/timolol combination group in patients with primary open-angle glaucoma or ocular hypertension.
A Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel Phase 2b/3 Study to Evaluate the Efficacy and Safety of KSR-001 in Patients With Dry Eye Syndrome
The purpose of this study is to evaluate the efficacy and safety of KSR-001 in patients with Dry Eye Syndrome
A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristic of KSR-001 in Healthy Male Volunteers
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetic characteristic of KSR-001.
100 Clinical Results associated with KUKJE PHARMA Co., Ltd.
0 Patents (Medical) associated with KUKJE PHARMA Co., Ltd.
100 Deals associated with KUKJE PHARMA Co., Ltd.
100 Translational Medicine associated with KUKJE PHARMA Co., Ltd.